SERPINE1 (P05121) variants and mutations
SERPINE1 (also known as P05121) is a human protein-coding gene encoding a plasminogen activator inhibitor 1 protein. It suppresses fibrinolysis by inhibiting tissue- and urokinase-type plasminogen activators. Excess activity favors thrombosis and fibrosis, whereas biallelic loss-of-function variants can cause a rare bleeding disorder with excessive fibrinolysis. This analysis covers 741 SERPINE1 variants and mutations. Of these, 93% have computational variant effect predictions. Disease context includes congenital plasminogen activator inhibitor type 1 deficiency, venous thromboembolism, and coronary artery disorder. Example SERPINE1 variants include Q2*, Q2R, and M3I.
Variant analysis overview
- Gene: SERPINE1
- Protein: P05121
- UniProt accession: P05121
- Organism: Homo sapiens
- Variants analyzed: 741
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 491 unspecified-consequence records; 105 missense variants; 119 synonymous variants; 16 frameshift variants; 2 in-frame deletions; 4 stop-gained variants; 2 splice-region variants; 2 substitution
- Prediction scores: 692 variants have prediction scores (93% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: congenital plasminogen activator inhibitor type 1 deficiency, venous thromboembolism, coronary artery disorder, ischemic stroke, Abnormal bleeding, hemorrhage, thrombotic disease, breast carcinoma, metabolic syndrome, glioblastoma, neoplasm, esophageal squamous cell carcinoma.
Protein structure and variant hotspots
- Protein features: 3 post-translational modification sites.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable SERPINE1 variants
Examples include Q2*, Q2R, M3I, S4C, S4P, P5T, P5L, A6S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2* (p.Gln2Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q2R (p.Gln2Arg), Ensembl rs1796146336, MetaLR 0.27, MetaSVM -0.91
- M3I (p.Met3Ile), ExAC rs745834082, TOPMed rs745834082, gnomAD rs745834082, REVEL 0.20, CADD 16.80
- S4C (p.Ser4Cys), NCI-TCGA Cosmic COSV5616, Variant assessed as somatic; moderate impact.
- S4P (p.Ser4Pro), Ensembl rs1796146934, MetaLR 0.36, MetaSVM -0.56
- P5T (p.Pro5Thr), gnomAD rs1302913603, REVEL 0.13, CADD 9.31
- P5L (p.Pro5Leu), gnomAD 7-101128407-C-T, REVEL 0.19, CADD 9.66
- A6S (p.Ala6Ser), gnomAD 7-101128409-G-T, REVEL 0.19, CADD 13.20
- A6D (p.Ala6Asp), gnomAD 7-101128410-C-A, REVEL 0.41, CADD 5.83
- A6A (p.Ala6Ala), gnomAD 7-101128411-C-G, CADD 5.63
- L7F (p.Leu7Phe), gnomAD 7-101128412-C-T, REVEL 0.06, CADD 7.21
- L7P (p.Leu7Pro), gnomAD 7-101128413-T-C, REVEL 0.52, CADD 17.70
- L7L (p.Leu7Leu), gnomAD 7-101128414-C-T, CADD 0.30
- T8A (p.Thr8Ala), Ensembl rs1584902704, MetaLR 0.24, MetaSVM -0.95
- T8P (p.Thr8Pro), Ensembl rs1584902704, REVEL 0.26, CADD 14.90
- T8S (p.Thr8Ser), rs1156277677, NCI-TCGA Cosmic COSV9977, TOPMed rs1156277677, gnomAD rs1156277677, REVEL 0.22, CADD 8.52, Variant assessed as somatic; moderate impact.
- T8H (p.Thr8His), gnomAD 7-101128413-T-TA, CADD 20.10
- T8T (p.Thr8Thr), gnomAD 7-101128417-C-T, CADD 8.95
- C9F (p.Cys9Phe), ExAC rs772178086, gnomAD rs772178086, REVEL 0.53, CADD 24.10
- C9G (p.Cys9Gly), NCI-TCGA Cosmic COSV5617, MetaLR 0.57, MetaSVM 0.38, Variant assessed as somatic; moderate impact.
- C9* (p.Cys9Ter), gnomAD 7-101128415-ACCTG, CADD 25.00
- C9Y (p.Cys9Tyr), gnomAD 7-101128419-G-A, REVEL 0.55, CADD 24.00
- C9W (p.Cys9Trp), gnomAD 7-101128420-C-G, REVEL 0.66, CADD 23.40
- L10L (p.Leu10Leu), rs775544655, gnomAD 7-101128423-A-G, CADD 0.38
- V11L (p.Val11Leu), gnomAD 7-101128424-G-C, REVEL 0.17, CADD 1.92
- V11I (p.Val11Ile), gnomAD 7-101128424-G-A, REVEL 0.10, CADD 2.28
- V11A (p.Val11Ala), gnomAD 7-101128425-T-C, REVEL 0.21, CADD 5.61
- L12R (p.Leu12Arg), TOPMed rs1796148467, MetaLR 0.58, MetaSVM 0.41
- L12L (p.Leu12Leu), rs760319461, gnomAD 7-101128427-C-T, CADD 6.58
- G13S (p.Gly13Ser), ExAC rs763507112, gnomAD rs763507112, REVEL 0.37, CADD 20.60, Uncertain significance, not specified
- G13V (p.Gly13Val), TOPMed rs1796148703, MetaLR 0.27, MetaSVM -0.69
- G13G (p.Gly13Gly), gnomAD 7-101128432-C-T, CADD 9.47
- L14L (p.Leu14Leu), rs1311674837, gnomAD 7-101128433-C-T, CADD 8.45
- L14V (p.Leu14Val), gnomAD 7-101128433-C-G, REVEL 0.31, CADD 22.70
- A15T (p.Ala15Thr), rs6092, ClinGen CA123260, ClinVar RCV000014541, ClinVar RCV001530150, REVEL 0.36, CADD 16.30, Benign/Likely benign, not specified; not provided; Congenital plasminogen activator inhibitor type 1 d
- A15V (p.Ala15Val), gnomAD 7-101128437-C-T, REVEL 0.29, CADD 16.00
- A15A (p.Ala15Ala), rs766786257, gnomAD 7-101128438-C-T, CADD 8.95
- L16F (p.Leu16Phe), gnomAD rs1411224107, REVEL 0.25, CADD 12.80
- V17A (p.Val17Ala), gnomAD rs1268101578, REVEL 0.17, CADD 13.30
- V17I (p.Val17Ile), rs6090, ClinGen CA4405511, ClinVar RCV000325357, ClinVar RCV001653713, REVEL 0.14, CADD 0.02, Benign, not specified; not provided; Congenital plasminogen activator inhibitor type 1 d
- V17V (p.Val17Val), rs1477871127, gnomAD 7-101128444-C-T, CADD 6.33
- F18S (p.Phe18Ser), ESP rs370185023, ExAC rs370185023, gnomAD rs370185023, REVEL 0.13, CADD 9.56
- F18Y (p.Phe18Tyr), ESP rs370185023, ExAC rs370185023, gnomAD rs370185023, MetaLR 0.26, MetaSVM -0.84
- G19A (p.Gly19Ala), TOPMed rs1178751523, gnomAD rs1178751523, MetaLR 0.23, MetaSVM -0.91
- G19D (p.Gly19Asp), TOPMed rs1178751523, gnomAD rs1178751523, REVEL 0.39, CADD 16.90
- G19V (p.Gly19Val), TOPMed rs1178751523, gnomAD rs1178751523, REVEL 0.14, CADD 14.50
- E20D (p.Glu20Asp), ExAC rs768073380, gnomAD rs768073380, REVEL 0.11, CADD 9.87
- G21V (p.Gly21Val), NCI-TCGA TCGA novel, MetaLR 0.31, MetaSVM -0.81, Variant assessed as somatic; moderate impact.
- A23V (p.Ala23Val), gnomAD rs1418764262, MetaLR 0.37, MetaSVM -0.67
- A23del (p.Ala23del), rs1796150695, gnomAD 7-101128457-TCTG-, CADD 8.15
- V24A (p.Val24Ala), ExAC rs753201992, TOPMed rs753201992, gnomAD rs753201992, REVEL 0.12, CADD 5.71
- V24L (p.Val24Leu), gnomAD 7-101128463-G-C, REVEL 0.13, CADD 0.22
- V24V (p.Val24Val), gnomAD 7-101128465-G-C, CADD 0.43
- H25P (p.His25Pro), rs2227647, ClinGen CA4405515, ClinVar RCV001454287, UniProt VAR 013086, REVEL 0.18, CADD 4.13, Likely benign, not provided
- H25Y (p.His25Tyr), gnomAD 7-101128466-C-T, REVEL 0.18, CADD 0.01
- H25H (p.His25His), rs1425845079, gnomAD 7-101128468-C-T, CADD 2.89
- H26N (p.His26Asn), NCI-TCGA Cosmic COSV9977, MetaLR 0.32, MetaSVM -0.79, Variant assessed as somatic; moderate impact.
- H26R (p.His26Arg), NCI-TCGA Cosmic COSV5616, REVEL 0.12, CADD 0.06, Variant assessed as somatic; moderate impact.
- H26Y (p.His26Tyr), gnomAD 7-101128469-C-T, REVEL 0.16, CADD 0.41
- H26Q (p.His26Gln), gnomAD 7-101128471-T-A, REVEL 0.15, CADD 0.24
- H26H (p.His26His), gnomAD 7-101128471-T-C, CADD 0.95
- P27H (p.Pro27His), ExAC rs777658507, gnomAD rs777658507, REVEL 0.23, CADD 0.05
- P27S (p.Pro27Ser), rs1163437425, NCI-TCGA Cosmic COSV5616, TOPMed rs1163437425, gnomAD rs1163437425, REVEL 0.16, CADD 1.58, Uncertain significance
- P27T (p.Pro27Thr), rs1163437425, ClinGen CA368594321, ClinVar RCV002245480, TOPMed rs1163437425, REVEL 0.17, CADD 2.70, Uncertain significance, Congenital plasminogen activator inhibitor type 1 deficiency
- P28A (p.Pro28Ala), TOPMed rs1213710187, gnomAD rs1213710187, REVEL 0.13, CADD 5.28
- P28L (p.Pro28Leu), ExAC rs754112992, TOPMed rs754112992, gnomAD rs754112992, REVEL 0.15, CADD 9.05
- P28Q (p.Pro28Gln), ExAC rs754112992, TOPMed rs754112992, gnomAD rs754112992, REVEL 0.11, CADD 4.61
- P28S (p.Pro28Ser), TOPMed rs1213710187, gnomAD rs1213710187, REVEL 0.11, CADD 7.60
- P28T (p.Pro28Thr), NCI-TCGA TCGA novel, MetaLR 0.34, MetaSVM -0.75, Variant assessed as somatic; moderate impact.
- P28H (p.Pro28His), gnomAD 7-101128471-TC-T, CADD 18.10
- P28P (p.Pro28Pro), gnomAD 7-101128477-A-G, CADD 5.45
- S29F (p.Ser29Phe), TOPMed rs1796153015, gnomAD rs1796153015, REVEL 0.15, CADD 7.46
- S29P (p.Ser29Pro), NCI-TCGA Cosmic COSV9977, MetaLR 0.26, MetaSVM -0.90, Variant assessed as somatic; moderate impact.
- S29T (p.Ser29Thr), Ensembl rs1562851529, REVEL 0.04, CADD 3.19
- Y30C (p.Tyr30Cys), Ensembl rs1796153434
- Y30H (p.Tyr30His), TOPMed rs969458866
- Y30* (p.Tyr30Ter), gnomAD 7-101128483-C-A, CADD 33.00
- Y30Y (p.Tyr30Tyr), rs756397063, gnomAD 7-101128483-C-T, CADD 2.79
- V31L (p.Val31Leu), 1000Genomes rs141347752, ESP rs141347752, ExAC rs141347752, TOPMed rs141347752, REVEL 0.15, CADD 11.30
- V31M (p.Val31Met), 1000Genomes rs141347752, ESP rs141347752, ExAC rs141347752, TOPMed rs141347752, REVEL 0.13, CADD 20.30
- H33Q (p.His33Gln), gnomAD 7-101128492-C-A, REVEL 0.03, CADD 0.00
- H33H (p.His33His), rs1305583558, gnomAD 7-101128492-C-T, CADD 0.38
- L34M (p.Leu34Met), NCI-TCGA Cosmic COSV5617, Variant assessed as somatic; moderate impact.
- L34V (p.Leu34Val), NCI-TCGA Cosmic COSV5617, MetaLR 0.04, MetaSVM -1.04, Variant assessed as somatic; moderate impact.
- L34L (p.Leu34Leu), rs1796154738, gnomAD 7-101128493-C-T, CADD 9.76
- L34P (p.Leu34Pro), gnomAD 7-101128494-T-C, REVEL 0.22, CADD 25.30
- A35S (p.Ala35Ser), NCI-TCGA Cosmic COSV9977, TOPMed rs1796155285, REVEL 0.08, CADD 18.20, Variant assessed as somatic; moderate impact.
- A35D (p.Ala35Asp), gnomAD 7-101128497-C-A, REVEL 0.20, CADD 23.40
- S36* (p.Ser36Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- S36L (p.Ser36Leu), NCI-TCGA TCGA novel, MetaLR 0.37, MetaSVM -0.64, Variant assessed as somatic; moderate impact.
- D37N (p.Asp37Asn), ExAC rs771977842, TOPMed rs771977842, gnomAD rs771977842, REVEL 0.24, CADD 22.40
- D37G (p.Asp37Gly), gnomAD 7-101128503-A-G, REVEL 0.64, CADD 29.10
- D37D (p.Asp37Asp), rs1280730027, gnomAD 7-101128504-C-T, CADD 13.70
- F38F (p.Phe38Phe), rs780207027, gnomAD 7-101128507-C-T, CADD 7.34
- G39E (p.Gly39Glu), Ensembl rs912771018
- G39R (p.Gly39Arg), TOPMed rs1246094084, gnomAD rs1246094084, REVEL 0.89, CADD 32.00
- G39V (p.Gly39Val), NCI-TCGA TCGA novel, MetaLR 0.74, MetaSVM 0.58, Variant assessed as somatic; moderate impact.
- G39W (p.Gly39Trp), TOPMed rs1246094084, gnomAD rs1246094084, REVEL 0.85, CADD 32.00
- G39G (p.Gly39Gly), gnomAD 7-101128510-G-T, CADD 8.50
- V40* (p.Val40Ter), NCI-TCGA Cosmic COSV5617, Variant assessed as somatic; high impact.
- V40A (p.Val40Ala), gnomAD rs1290883786, REVEL 0.58, CADD 25.40
- V40L (p.Val40Leu), TOPMed rs910203879, MetaLR 0.16, MetaSVM -0.85
- V40M (p.Val40Met), gnomAD 7-101128511-G-A, REVEL 0.29, CADD 17.10
- R41G (p.Arg41Gly), 1000Genomes rs549581756, ExAC rs549581756, TOPMed rs549581756, gnomAD rs549581756, REVEL 0.36, CADD 25.90
- R41K (p.Arg41Lys), ExAC rs768221689, REVEL 0.21, CADD 16.70
- V42L (p.Val42Leu), ExAC rs775950945, gnomAD rs775950945, REVEL 0.32, CADD 23.30
- V42V (p.Val42Val), rs1345424388, gnomAD 7-101128519-G-A, CADD 14.20
- Q44R (p.Gln44Arg), gnomAD 7-101128524-A-G, REVEL 0.28, CADD 16.30
- Q45R (p.Gln45Arg), gnomAD 7-101128527-A-G, REVEL 0.36, CADD 24.70
- V46A (p.Val46Ala), TOPMed rs1174856192, REVEL 0.12, CADD 22.90
- V46V (p.Val46Val), rs761555705, gnomAD 7-101128531-G-A, CADD 13.30
- A47T (p.Ala47Thr), ExAC rs769368888, gnomAD rs769368888, REVEL 0.27, CADD 22.40
- A47V (p.Ala47Val), rs772841880, NCI-TCGA Cosmic COSV5617, ExAC rs772841880, TOPMed rs772841880, REVEL 0.13, CADD 2.21, Variant assessed as somatic; moderate impact.
- A47A (p.Ala47Ala), rs759962938, gnomAD 7-101128534-G-A, CADD 1.36
- Q48* (p.Gln48Ter), ExAC rs767807262, TOPMed rs767807262, gnomAD rs767807262, CADD 34.00
- Q48R (p.Gln48Arg), gnomAD rs1183093492, REVEL 0.10, CADD 13.70
- Q48K (p.Gln48Lys), gnomAD 7-101128535-C-A, REVEL 0.14, CADD 5.98
- A49S (p.Ala49Ser), NCI-TCGA Cosmic COSV5617, REVEL 0.24, CADD 15.00, Variant assessed as somatic; moderate impact.
- A49T (p.Ala49Thr), ExAC rs753220162, TOPMed rs753220162, gnomAD rs753220162, REVEL 0.22, CADD 19.30
- A49V (p.Ala49Val), gnomAD rs1796158675, REVEL 0.18, CADD 18.50
- S50C (p.Ser50Cys), rs1412176159, ClinGen CA368594747, ClinVar RCV001165029, TOPMed rs1412176159, REVEL 0.45, CADD 25.40, Uncertain significance, Congenital plasminogen activator inhibitor type 1 deficiency
- S50F (p.Ser50Phe), rs1412176159, ClinGen CA368594751, ClinVar RCV001727412, TOPMed rs1412176159, REVEL 0.43, CADD 25.80, Uncertain significance, not provided
- S50P (p.Ser50Pro), gnomAD 7-101128541-T-C, REVEL 0.40, CADD 23.60
- K51R (p.Lys51Arg), TOPMed rs533560118, gnomAD rs533560118, REVEL 0.11, CADD 18.10
- D52Y (p.Asp52Tyr), NCI-TCGA Cosmic COSV9977, MetaLR 0.18, MetaSVM -0.82, Variant assessed as somatic; moderate impact.
- D52N (p.Asp52Asn), gnomAD 7-101128547-G-A, REVEL 0.18, CADD 26.10
- D52E (p.Asp52Glu), gnomAD 7-101128549-C-A, REVEL 0.11, CADD 22.90
- R53C (p.Arg53Cys), rs761039040, ClinGen CA4405532, ClinVar RCV004297165, ExAC rs761039040, REVEL 0.56, CADD 24.80, Uncertain significance, not specified
- R53H (p.Arg53His), ExAC rs764266756, TOPMed rs764266756, gnomAD rs764266756, REVEL 0.41, CADD 22.30
- R53S (p.Arg53Ser), NCI-TCGA Cosmic COSV9977, MetaLR 0.37, MetaSVM -0.60, Variant assessed as somatic; moderate impact.
- R53G (p.Arg53Gly), gnomAD 7-101128550-C-G, REVEL 0.18, CADD 19.40
- R53R (p.Arg53Arg), rs2116596471, gnomAD 7-101128552-C-T, CADD 14.10
- N54D (p.Asn54Asp), Ensembl rs1562851602
- N54S (p.Asn54Ser), NCI-TCGA Cosmic COSV5616, REVEL 0.83, CADD 27.80, Variant assessed as somatic; moderate impact.
- N54N (p.Asn54Asn), rs373294605, gnomAD 7-101128555-C-T, CADD 6.21
- V55M (p.Val55Met), TOPMed rs1384573586, gnomAD rs1384573586, REVEL 0.41, CADD 22.00
- V55E (p.Val55Glu), gnomAD 7-101128557-T-A, REVEL 0.86, CADD 32.00
- V55V (p.Val55Val), rs757339755, gnomAD 7-101128558-G-A, CADD 14.00
- F57F (p.Phe57Phe), gnomAD 7-101128564-C-T, CADD 14.90
- S58F (p.Ser58Phe), rs1313791756, gnomAD 7-101128564-C-CT, CADD 32.00
- S58L (p.Ser58Leu), gnomAD 7-101128566-C-T, REVEL 0.97, CADD 32.00
- S58S (p.Ser58Ser), gnomAD 7-101128567-A-C, CADD 5.74
- P59H (p.Pro59His), gnomAD rs1468978490, MetaLR 0.69, MetaSVM 0.66
- P59L (p.Pro59Leu), gnomAD rs1468978490, REVEL 0.81, CADD 29.60
- P59T (p.Pro59Thr), TOPMed rs1562851610, REVEL 0.84, CADD 26.90
- P59P (p.Pro59Pro), rs1484797771, gnomAD 7-101128570-C-T, CADD 12.10
- Y60H (p.Tyr60His), Ensembl rs1584902848
- Y60Y (p.Tyr60Tyr), rs376485687, gnomAD 7-101128573-T-C, CADD 5.99
- Y60* (p.Tyr60Ter), gnomAD 7-101128573-T-G, CADD 35.00
- G61R (p.Gly61Arg), NCI-TCGA Cosmic COSV9977, MetaLR 0.21, MetaSVM -0.67, Variant assessed as somatic; moderate impact.
- G61G (p.Gly61Gly), rs1376860576, gnomAD 7-101128576-G-C, CADD 14.30
- V62L (p.Val62Leu), NCI-TCGA TCGA novel, 1000Genomes rs564909482, ExAC rs564909482, TOPMed rs564909482, Variant assessed as somatic; moderate impact.
- V62M (p.Val62Met), 1000Genomes rs564909482, ExAC rs564909482, TOPMed rs564909482, gnomAD rs564909482, REVEL 0.11, CADD 25.30
- V62V (p.Val62Val), gnomAD 7-101128579-G-T, CADD 11.70
- A63A (p.Ala63Ala), rs1796161901, gnomAD 7-101128582-C-T, CADD 14.20
- S64L (p.Ser64Leu), rs758271488, ClinGen CA4405538, NCI-TCGA Cosmic COSV9977, ClinVar RCV000389274, REVEL 0.37, CADD 29.70, Uncertain significance, Congenital plasminogen activator inhibitor type 1 deficiency
- S64S (p.Ser64Ser), rs370646624, gnomAD 7-101128585-G-C, CADD 3.34
- V65A (p.Val65Ala), ExAC rs781150795, gnomAD rs781150795, REVEL 0.35, CADD 24.90
- V65L (p.Val65Leu), ExAC rs768436491, TOPMed rs768436491, gnomAD rs768436491, REVEL 0.49, CADD 24.70
- V65M (p.Val65Met), ExAC rs768436491, TOPMed rs768436491, gnomAD rs768436491, REVEL 0.59, CADD 28.50
- V65V (p.Val65Val), rs747672378, gnomAD 7-101128588-G-A, CADD 8.56
- A67V (p.Ala67Val), rs867364951, Ensembl rs867364951, AlphaMissense 0.39, MetaLR 0.78, Variant assessed as somatic; moderate impact.
- A67T (p.Ala67Thr), gnomAD 7-101128592-G-A, REVEL 0.60, MetaLR 0.64
- A67A (p.Ala67Ala), rs1796163359, gnomAD 7-101128594-C-T, CADD 14.30
- M68I (p.Met68Ile), gnomAD rs886882915, REVEL 0.79, CADD 26.10
- M68T (p.Met68Thr), ExAC rs769345666, gnomAD rs769345666, REVEL 0.91, CADD 26.50
- M68V (p.Met68Val), TOPMed rs1172504400, gnomAD rs1172504400, REVEL 0.55, CADD 22.60
- M68L (p.Met68Leu), gnomAD 7-101128595-A-T, REVEL 0.69, MetaLR 0.52
- L69F (p.Leu69Phe), ExAC rs772860311, TOPMed rs772860311, gnomAD rs772860311, REVEL 0.64, CADD 23.40
- L69V (p.Leu69Val), ExAC rs772860311, TOPMed rs772860311, gnomAD rs772860311, REVEL 0.45, CADD 21.00
- Q70H (p.Gln70His), ExAC rs748885714, gnomAD rs748885714, REVEL 0.38, CADD 25.80
- Q70R (p.Gln70Arg), gnomAD 7-101128602-A-G, REVEL 0.39, MetaLR 0.11
- L71L (p.Leu71Leu), gnomAD 7-101128604-C-T, CADD 3.48
- L71P (p.Leu71Pro), gnomAD 7-101128605-T-C, REVEL 0.38, MetaLR 0.72
- T72K (p.Thr72Lys), ExAC rs772448319, MetaLR 0.08, MetaSVM -1.08
- T72R (p.Thr72Arg), gnomAD 7-101128608-C-G, REVEL 0.26, MetaLR 0.08
- T73A (p.Thr73Ala), rs374379570, ClinGen CA4405548, ClinVar RCV004453371, ESP rs374379570, REVEL 0.09, CADD 13.00, Uncertain significance, not specified
- T73T (p.Thr73Thr), gnomAD 7-101128612-A-G, CADD 0.89
- G74R (p.Gly74Arg), ExAC rs761071307, TOPMed rs761071307, gnomAD rs761071307, REVEL 0.07, CADD 17.60
- G74G (p.Gly74Gly), gnomAD 7-101128615-A-G, CADD 8.10
Public SERPINE1 analysis runs
- SERPINE1 analysis run — SERPINE1 (741 variants) — completed 2026-08-19